К содержанию
Dr. Tara EinullaevaMedical oncologist

Cancer glossary

Pertuzumab: why it is added to trastuzumab in HER2-positive cancer

Pertuzumab is a second antibody against HER2. When it is given with trastuzumab, how it is given, what the combined under-the-skin form is and which side effects to expect.

Written and medically reviewed by

Dr. Tara Einullaeva

Medical oncologist, 9 years in practice. Credentials · reviewed 19 October 2026

In short

Pertuzumab (brand name Perjeta) is a monoclonal antibody against HER2. It is given together with trastuzumab: together they block HER2 more strongly than either alone.

How it appears in your prescription

  • ‘Pertuzumab 840 mg loading dose, then 420 mg every 3 weeks + trastuzumab + docetaxel’.
  • ‘Pertuzumab/trastuzumab SC’ — the combined under-the-skin form.

What it means

According to the US National Cancer Institute, pertuzumab is approved for HER2-positive breast cancer: before surgery (neoadjuvant), after surgery when the risk is high, and in metastatic cancer. Before surgery, dual blockade raises the chance of a pathologic complete response. Approved uses in each country are set by the local label and guidelines.

Side effects

The most common is diarrhea, especially with chemotherapy. Also rash, fatigue and low blood counts. As with trastuzumab, heart function is checked with echocardiograms on schedule (cardiotoxicity).

Tell your doctor about diarrhea more than 4 times a day, shortness of breath or swelling.

Questions to ask your doctor

  • Do I need dual HER2 blockade, or is trastuzumab enough?
  • How many infusions before and after surgery?
  • How do I manage diarrhea and when should I call?

Sources

  1. Pertuzumab — National Cancer Institute
  2. Targeted Therapy for Breast Cancer — National Cancer Institute
  3. Drugs Approved for Breast Cancer — National Cancer Institute

FAQ

Related terms

This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.

Related articles

All blog articles